Monoclonal antibody treatment of symptomatic COVID-19 in pregnancy: initial report

Am J Obstet Gynecol. 2021 Dec;225(6):688-689. doi: 10.1016/j.ajog.2021.08.025. Epub 2021 Aug 25.

Authors

Jonathan S Hirshberg¹, Emily Cooke², Megan C Oakes³, Anthony O Odibo³, Nandini Raghuraman³, Jeannie C Kelly³

Affiliations

¹ Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO; Center for Outpatient Health, Barnes-Jewish Hospital, 4901 Forest Park Ave., Suite 905, St. Louis, MO 63108. Electronic address: Jhirshberg@wustl.edu.
² Department of Pharmacy, Barnes-Jewish Hospital, St Louis, MO.
³ Department of Obstetrics and Gynecology, Washington University School of Medicine, St Louis, MO.

No abstract available

Publication types

Letter

MeSH terms

Adult
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Antibodies, Neutralizing / therapeutic use*
COVID-19 Drug Treatment*
Drug Combinations
Female
Humans
Pregnancy
Pregnancy Complications, Infectious / drug therapy*
SARS-CoV-2 / immunology*
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neutralizing
Drug Combinations
casirivimab and imdevimab drug combination